97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01658605
(ClinicalTrials.gov)
February 201324/5/2012A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative ColitisA Phase II, 20-week, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Proof of Concept Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative ColitisColitis, UlcerativeDrug: GSK1605786;Other: PlaceboGlaxoSmithKlineNULLWithdrawn18 YearsN/ABoth0Phase 2Belgium;Netherlands;United Kingdom
2EUCTR2011-002818-37-BE
(EUCTR)
15/02/201203/10/2011A Phase II study to investigate GSK1605786 fo the treatment of patients with Ulcerative Colitis.A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis. Subjects with Active Ulcerative Colitis.
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: GSK1605786A
Product Code: GSK1605786A
GlaxoSmithKline Research & Development LtdNULLNot RecruitingFemale: yes
Male: yes
45Phase 2Belgium;Netherlands;United Kingdom
3EUCTR2011-002818-37-GB
(EUCTR)
08/02/201207/11/2011A Phase II study to investigate GSK1605786 fo the treatment of patients with Ulcerative Colitis.A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis. Subjects with Active Ulcerative Colitis.
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: GSK1605786A
Product Code: GSK1605786A
GlaxoSmithKline Research & Development LtdNULLNot RecruitingFemale: yes
Male: yes
45Phase 2Netherlands;United Kingdom
4EUCTR2011-002818-37-NL
(EUCTR)
03/01/201216/02/2012A Phase II study to investigate GSK1605786 fo the treatment of patients with Ulcerative Colitis.A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis. Subjects with Active Ulcerative Colitis.
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: GSK1605786A
Product Code: GSK1605786A
GlaxoSmithKline Research & Development LtdNULLNot RecruitingFemale: yes
Male: yes
45Phase 2Netherlands;United Kingdom